Why the study?
Does first-line therapy with drug combinations improve survival in adults with pulmonary arterial hypertension?
Does first-line therapy with drug combinations improve survival in adults with pulmonary arterial hypertension?
First-line combination therapy targeting multiple biological pathways is associated with improved survival in patients with pulmonary arterial hypertension.
May support considering multi-pathway combinations in PAH; leaves open confirmation by randomized trials.
Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.
No takes yet. Share an insight, caveat, or question.
Ruopp et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: